INmune Bio Inc. (INMB)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20261 patent granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to INmune Bio Inc.’s names, not what it holds today.
4 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Oct 24, 2023 | 11,793,836 | Method for treating complications related to acute or chronic hyperglycemia | Pharmaceuticals | INmune Bio Inc. |
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Oct 16, 2025 | 2025/0321234 | METHOD FOR DETECTING ANTI-DRUG ANTIBODIES AGAINST SELF-ASSEMBLING TRIMERIC BIOLOGICS USING AN AFFINITY CAPTURE ELUTION-PROTEIN A/G ASSAY | Analysis of biological materials | INmune Bio Inc. |
| Sep 18, 2025 | 2025/0288669 | HUMAN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELL LINE & APPLICATIONS FOR TREATING CANCER | Pharmaceuticals | INmune Bio Inc. |
| Aug 4, 2022 | 2022/0241374 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | Pharmaceuticals | INmune Bio Inc. |
| Sep 17, 2020 | 2020/0289576 | METHOD FOR TREATING COMPLICATIONS RELATED TO ACUTE OR CHRONIC HYPERGLYCEMIA | Pharmaceuticals | INmune Bio Inc. · patent 11,793,836 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.